Perrine Courlet1, Monia Guidi1,2, Anaïs Glatard1,3, Susana Alves Saldanha1, Matthias Cavassini4, Thierry Buclin1, Catia Marzolini5, Chin B Eap2,3, Laurent A Decosterd1, Chantal Csajka1,2. 1. Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. 2. School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland. 3. Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Hospital of Cery, Lausanne University Hospital and University of Lausanne, Prilly, Switzerland. 4. Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. 5. Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Switzerland.
Abstract
AIMS: The aims of this study were to characterize escitalopram pharmacokinetic profile, to identify factors influencing drug exposure, notably drug-drug interactions with antiretrovirals, and to simulate expected exposure under standard dosage regimen. METHODS: A population pharmacokinetic analysis was performed using NONMEM. A total of 159 plasma concentration measurements were obtained from 39 human immunodeficiency virus (HIV)-infected and 71 uninfected psychiatric patients. The influence of age, weight, sex, HIV and psychiatric cohorts, racemic citalopram treatment, and comedications on oral clearance was examined. Simulations served to calculate the percentage of patients expected to be under- or over-exposed, considering established therapeutic targets (15-80 ng/mL). RESULTS: A 1-compartment model with first-order absorption and elimination described the data adequately. The average escitalopram clearance and volume of distribution were 23.1 L/h (interindividual variability 51%), and 920 L, respectively. Escitalopram disposition did not differ between HIV-infected and uninfected patients, and was not affected by antiretroviral treatments. Coadministration of at least 1 proton-pump inhibitor (CYP2C19 inhibitor) modestly influenced escitalopram elimination (clearance decreased by 19%), with limited clinical relevance. Model-based simulations showed that, under a standard regimen of 10 mg once daily, a significant proportion of patients (56%) might be under-exposed. CONCLUSION: The variability in escitalopram disposition is large and poorly explained by demographic, clinical and environmental covariates, thus suggesting a role for dosage individualization based on therapeutic drug monitoring in case of poor clinical response. Escitalopram disposition is modestly impacted by comedications and therefore no a priori dosage adjustments are needed in patients receiving antiretroviral treatments, including boosted regimens.
AIMS: The aims of this study were to characterize escitalopram pharmacokinetic profile, to identify factors influencing drug exposure, notably drug-drug interactions with antiretrovirals, and to simulate expected exposure under standard dosage regimen. METHODS: A population pharmacokinetic analysis was performed using NONMEM. A total of 159 plasma concentration measurements were obtained from 39 human immunodeficiency virus (HIV)-infected and 71 uninfected psychiatricpatients. The influence of age, weight, sex, HIV and psychiatric cohorts, racemic citalopram treatment, and comedications on oral clearance was examined. Simulations served to calculate the percentage of patients expected to be under- or over-exposed, considering established therapeutic targets (15-80 ng/mL). RESULTS: A 1-compartment model with first-order absorption and elimination described the data adequately. The average escitalopram clearance and volume of distribution were 23.1 L/h (interindividual variability 51%), and 920 L, respectively. Escitalopram disposition did not differ between HIV-infected and uninfected patients, and was not affected by antiretroviral treatments. Coadministration of at least 1 proton-pump inhibitor (CYP2C19 inhibitor) modestly influenced escitalopram elimination (clearance decreased by 19%), with limited clinical relevance. Model-based simulations showed that, under a standard regimen of 10 mg once daily, a significant proportion of patients (56%) might be under-exposed. CONCLUSION: The variability in escitalopram disposition is large and poorly explained by demographic, clinical and environmental covariates, thus suggesting a role for dosage individualization based on therapeutic drug monitoring in case of poor clinical response. Escitalopram disposition is modestly impacted by comedications and therefore no a priori dosage adjustments are needed in patients receiving antiretroviral treatments, including boosted regimens.
Authors: Yuyan Jin; Bruce G Pollock; Ellen Frank; Jeff Florian; Margaret Kirshner; Andrea Fagiolini; David J Kupfer; Marc R Gastonguay; Gail Kepple; Yan Feng; Robert R Bies Journal: J Clin Pharmacol Date: 2009-02 Impact factor: 3.126
Authors: Eva Choong; Lina Quteineh; Jean-René Cardinaux; Mehdi Gholam-Rezaee; Frederik Vandenberghe; Maria Dobrinas; Guido Bondolfi; Manuela Etter; Laurent Holzer; Pierre Magistretti; Armin von Gunten; Martin Preisig; Peter Vollenweider; Jacques S Beckmann; François P Pralong; Gerard Waeber; Zoltan Kutalik; Philippe Conus; Murielle Bochud; Chin B Eap Journal: JAMA Psychiatry Date: 2013-10 Impact factor: 21.596
Authors: Ayman Akil; Robert R Bies; Bruce G Pollock; Dimitrios Avramopoulos; D P Devanand; Jacobo E Mintzer; Anton P Porsteinsson; Lon S Schneider; Daniel Weintraub; Jerome Yesavage; David M Shade; Constantine G Lyketsos Journal: J Pharmacokinet Pharmacodyn Date: 2015-11-26 Impact factor: 2.745